CA3136153A1 - Compounds and methods for treating inflammatory disorders - Google Patents

Compounds and methods for treating inflammatory disorders Download PDF

Info

Publication number
CA3136153A1
CA3136153A1 CA3136153A CA3136153A CA3136153A1 CA 3136153 A1 CA3136153 A1 CA 3136153A1 CA 3136153 A CA3136153 A CA 3136153A CA 3136153 A CA3136153 A CA 3136153A CA 3136153 A1 CA3136153 A1 CA 3136153A1
Authority
CA
Canada
Prior art keywords
compound
pharmaceutical composition
administered
ibu
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3136153A
Other languages
English (en)
French (fr)
Inventor
Charles D. Nichols
Gerald BILLAC
David E. Nichols
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Louisiana State University
Original Assignee
Louisiana State University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Louisiana State University filed Critical Louisiana State University
Publication of CA3136153A1 publication Critical patent/CA3136153A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/56—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/56—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
    • C07C217/60—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms linked by carbon chains having two carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
CA3136153A 2019-04-12 2020-04-13 Compounds and methods for treating inflammatory disorders Pending CA3136153A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962833140P 2019-04-12 2019-04-12
US62/833,140 2019-04-12
PCT/US2020/027981 WO2020210823A1 (en) 2019-04-12 2020-04-13 Compounds and methods for treating inflammatory disorders

Publications (1)

Publication Number Publication Date
CA3136153A1 true CA3136153A1 (en) 2020-10-15

Family

ID=72751451

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3136153A Pending CA3136153A1 (en) 2019-04-12 2020-04-13 Compounds and methods for treating inflammatory disorders

Country Status (9)

Country Link
US (2) US12398093B2 (https=)
EP (2) EP3952851B1 (https=)
JP (1) JP7596296B2 (https=)
KR (1) KR20220008264A (https=)
CN (2) CN113784709B (https=)
AU (1) AU2020271915B2 (https=)
BR (1) BR112021020424A2 (https=)
CA (1) CA3136153A1 (https=)
WO (1) WO2020210823A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4377293A4 (en) * 2021-07-26 2025-06-25 Board of Supervisors of Louisiana State University and Agricultural and Mechanical College COMPOUNDS AND METHODS FOR THE TREATMENT OF 5-HT2-RESPONSIBLE DISEASES

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE2151519A1 (en) 2021-12-10 2023-06-11 Amidea Sweden Ab 2-(2,5-dimethoxyphenyl)ethanamine and uses thereof
WO2024010765A1 (en) * 2022-07-05 2024-01-11 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Compositions for treating 5-ht2 conditions and methods of using the same
WO2024191924A2 (en) * 2023-03-10 2024-09-19 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Compositions and methods of use thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007016190A2 (en) * 2005-07-28 2007-02-08 Duke University Antiparkinsonian action of phenylisopropylamines
US9642819B2 (en) * 2008-07-10 2017-05-09 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical Low dosage serotonin 5-HT2A receptor agonist to suppress inflammation
EP2884962B1 (en) * 2012-08-17 2019-05-01 Smartek International LLC Preparation of desiccated liposomes for use in compressible delivery systems
US20200078335A1 (en) * 2017-05-01 2020-03-12 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Compositions and methods to reduce pathogenesis
GB201715919D0 (en) 2017-09-29 2017-11-15 Gw Res Ltd use of cannabinoids in the treatment of epilepsy

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4377293A4 (en) * 2021-07-26 2025-06-25 Board of Supervisors of Louisiana State University and Agricultural and Mechanical College COMPOUNDS AND METHODS FOR THE TREATMENT OF 5-HT2-RESPONSIBLE DISEASES

Also Published As

Publication number Publication date
CN113784709B (zh) 2024-05-10
US20220119340A1 (en) 2022-04-21
EP4685135A3 (en) 2026-04-15
EP4685135A2 (en) 2026-01-28
KR20220008264A (ko) 2022-01-20
BR112021020424A2 (pt) 2021-12-21
JP2022527401A (ja) 2022-06-01
WO2020210823A1 (en) 2020-10-15
JP7596296B2 (ja) 2024-12-09
EP3952851B1 (en) 2025-12-03
EP3952851A4 (en) 2023-01-11
AU2020271915A1 (en) 2021-11-04
US12398093B2 (en) 2025-08-26
CN113784709A (zh) 2021-12-10
AU2020271915B2 (en) 2025-10-09
EP3952851A1 (en) 2022-02-16
US20260070872A1 (en) 2026-03-12
CN118384143A (zh) 2024-07-26

Similar Documents

Publication Publication Date Title
US20260070872A1 (en) Compounds and methods for treating inflammatory disorders
KR102630889B1 (ko) 키나제를 조절하는 화합물의 고형 형태
CN109820853B (zh) 取代的杂环化合物在制备治疗癌症药物中的用途
CN116650500B (zh) 治疗癌症的方法
US20080254106A1 (en) Use Of Pirlindole For The Treatment Of Diseases Which Are Characterized By Proliferation Of T-Lymphocytes And/Or Hyperproliferation Of Keratinocytes In Particular Atopic Dermatitis And Psoriasis
US11236044B2 (en) Selective inhibitors of 12(S)-lipoxygenase (12-LOX) and methods for use of the same
KR20190031518A (ko) 치환된 디아자헤테로비시클릭 화합물 및 그의 용도
JP2018525414A (ja) 癌を処置するための方法
CN119118926A (zh) Kv7通道激活剂组合物和使用方法
US9981043B2 (en) Analgesic conjugates
CN112105602A (zh) 基于喹啉和异喹啉的hdac抑制剂及其使用方法
MX2015007269A (es) Composiciones que comprenden vortioxetina y donepezilo.
JPH09511483A (ja) α−２−アドレノセプター作動剤として有用な６−（２−イミダゾリニルアミノ）キノリン化合物
JP2008526948A (ja) 抗マラリア活性を有する９ａ−カルバモイルおよびチオカルバモイルアザライド
US20230339942A1 (en) Inhibitors of ubiquitin specific peptidase 22 (usp22) and uses thereof for treating diseases and disorders
HK40056643A (en) Compounds and methods for treating inflammatory disorders
KR20130130802A (ko) 보르트만닌 유사체의 결정질 형태의 조성물 및 이의 사용 방법
EP4308565A1 (en) Compositions and methods for treating neurologic diseases
JPWO2005011674A1 (ja) 気管支喘息の予防及び／または治療剤
JP2000500765A (ja) ロイコトリエン拮抗剤としてのジオール含有キノリン誘導体
US20250270205A1 (en) Compositions and methods for inhibiting trem-1
KR102553153B1 (ko) 포유류에서 질환을 치료하기 위한 신규한 다중표적 약물
WO2024059853A2 (en) Haph analogs and therapeutic and diagnostic uses thereof
HK40096678A (zh) 用於预防或治疗纤维化的药物组合物
WO2018181820A1 (ja) 複素環化合物

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20240410

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250318

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250318

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250318

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250414

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250812

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250822

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250924

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250924